Parasites, Hosts and Diseases

The Korea Society for Parasitology and Tropical Medicine (대한기생충학·열대의학회)
권호 표지
DOI QR코드

DOI QR Code

Anti-leishmanial Effects of Trinitroglycerin in BALB/C Mice Infected with Leishmania major via Nitric Oxide Pathway

  • Published : 2009.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

This study investigated whether trinitroglycerine (TNG) as nitric oxide (NO) releasing agent had anti-leishmanial effects and mediated pathology in BALB/c mice infected with Leishmania major. Cutaneous leishmaniasis (CL), a zoonotic infection caused by leishmania protozoa is still one of the health problems in the world and in Iran. NO is involved in host immune responses against intracellular L. major, and leishmania killing by macrophages is mediated by this substance. Moreover, application of CL treatment with NO-donors has been recently indicated. In our study, TNG was used for its ability to increase NO and to modify CL infection in mice, in order to evaluate NO effects on lesion size and formation, parasite proliferation inside macrophages, amastigote visceralization in target organs, and NO induction in plasma and organ suspensions. Data obtained in this study indicated that TNG increased plasma and liver-NO, reduced lesion sizes, removed amastigotes from lesions, livers, spleens, and lymph nodes, declined proliferation of amastigotes, hepatomegaly, and increased survival rate. However, TNG reduced spleen-NO and had no significant effects on spelenomegaly. The results show that TNG therapy reduced leishmaniasis and pathology in association with raised NO levels. TNG had some antiparasitic activity by reduction of positive smears from lesions, livers, spleens, and lymph nodes, which could emphasize the role of TNG to inhibit visceralization of L. major in target organs.

Keywords

References

  1. Mahmoodi M, Khamesipour A, Dowlati Y, Rafati S, Momeni AZ, Emamjomeh M, Hejazi E, Modabber F. Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG. Clin Exp Immunol 2003; 134: 303-308 https://doi.org/10.1046/j.1365-2249.2003.02299.x
  2. Faryadi M, Mohebali M. Alterations of serum zinc, copper and iron concentrations in patients with acute and chronic cutaneous leishmaniasis. Iranian J Publ Health 2003; 32: 53-58
  3. Salih Gurel M, Ulukanligil M, Ozbilge H. Cutaneous leishmaniasis in Sanliurfa: epidemiologic and clinical features of the last four years (1997-2000). Int J Dermatol 2002; 41: 32-37 https://doi.org/10.1046/j.0011-9059.2001.01396.x
  4. Khalid AF, Abdalla MN, Mohomed OH, Toum AM, Magzoub MA, Siddig MA. In vitro assessment of anti-cutaneous leishmaniasis activity of some sudanese plants. Turkiye Parazitoloji Dergisi 2005; 29: 3-6
  5. Nahrevanian H, Farahmand M, Aghighi Z, Assmar A, Amirkhani A. Pharmacological evaluation of anti-leishmanial activity by in vivo nitric oxide modulation in BALB/c mice infected with Leishmania major MRHO/IR/75/ER: an Iranian strain of cutaneous leishmaniasis. Exp Parasitol 2007; 116: 233-240 https://doi.org/10.1016/j.exppara.2007.01.002
  6. Scott PH. Immunologic memory in cutaneous leishmaniasis. Cell Microbiol 2005; 7: 1707-1713 https://doi.org/10.1111/j.1462-5822.2005.00626.x
  7. Croft S, Seifert K, Yardley V. Current scenario of drug development for leishmaniasis. Indian J Med Res 2006; 123: 399-410
  8. Holzmuller P, Sereno D, Cavaleyra M, Mangot I, Daulouede S, Vincendeau P, Lemesre J. Nitric oxide-mediated proteasome-dependent oligonucleosomal DNA fragmentation in Leishmania amazonensis amastigotes. Infect Immunol 2002; 70: 3727-3735 https://doi.org/10.1128/IAI.70.7.3727-3735.2002
  9. Stebut E. Immunology of cutaneous leishmaniasis: the role of mast cells, phagocytes and dendritic cells for protective immunity. Eur J Dermatol 2007; 17: 115-122 https://doi.org/10.1684/ejd.2007.0122
  10. Spahl UD, Berendji-Grun D, Suschek VB, Kolb-Bachofen V, Kroncke C. Regulation of zinc homeostasis by inducible NO synthasederived NO: nuclear metallothionein translocation and intranuclear $Zn^{2+}$ release (Ed.). Louis J. Ignarro, University of California School of Medicine 2003
  11. Kharazi SH, Zavaran Hosseini A, Tiraihi T. The role of overproduction of nitric oxide in apoptosis of BALB/c mice macrophages infected with Leishmania major in vitro. Iranian J Allerg Asthm Immunol 2003; 2: 209-214
  12. Colassanti M, Gradani L, Mattu M, Persichini T, Salvati L, Venturini G, Ascenzi P. Molecular bases for the anti-parasitic effect of NO (review). Int J Mol Med 2002; 9: 131-134
  13. Mossalayi MD, Arock M, Mazier D, Vincendeau P, Vouldoukis I. The human immune response during cutaneous leishmaniasis: no problem. Parasitol Today 1999; 15: 342-345 https://doi.org/10.1016/S0169-4758(99)01477-5
  14. Megson LI. Nitric oxide donor drugs. Drug Future 2000; 25: 701-715 https://doi.org/10.1358/dof.2000.025.07.858691
  15. Giudice A, Camada I, Leopoldo PTG, Pereira JMB, Riley LW, Wilson ME, Ho JL, de Jesus AR, Carvalho EM, Almeida RP. Resistance of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis to nitric oxide correlates with disease severity in tegumentary leishmaniasis. BMC Infec Dis 2007; 7: 7 https://doi.org/10.1186/1471-2334-7-7
  16. Holzmuller P, Sereno D, Cavaleyra M, Mangot I, Daulouede S, Vincendeau P, Lemesre JL. Nitric oxide-mediated proteasomedependent oligonucleosomal DNA fragmentation in Leishmania amazonensis amastigotes. Infect Immunol 2002; 70: 3727-3735 https://doi.org/10.1128/IAI.70.7.3727-3735.2002
  17. Erel O, Kocyigit A, Bulut V, Gurel M. Reactive nitrogen and oxygen intermediates in patients with cutaneouse leishmaniasis. Mem Inst Osw Cruz 1999; 94: 179-183 https://doi.org/10.1590/S0074-02761999000200009
  18. Nassiri-Kashani M, Firooz A, Khamesipour A, Mojtahed F, Nilforoushzadeh M, Hejazi H, Bouzari N, Dowlati Y. A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 2005; 19: 80-83 https://doi.org/10.1111/j.1468-3083.2004.01133.x
  19. Kolaczinski J, Brooker S, Reyburn H, Rowland M. Epidemiology of anthroponotic cutaneous leishmaniasis in Afghan refugee camps in North-West Pakistan. Trans R Soc Trop Med Hyg 2004; 98: 373-378 https://doi.org/10.1016/j.trstmh.2003.11.003
  20. Jaafari MR, Behravan J, Bodagh Abadi A, Ramezani M. Evaluation of leishmanicidal effect of Euphorbia myrsinites extract by in vitro antileishmanial assay using promastigote of Leishmania major. Iranian J Basic Med Sc 2005; 8: 295-298
  21. Zeina B, Banfield C, Assad SA. Topical glycerine trinitrate: a possible treatment for cutaneouse leishmaniasis. Clin Exp Dermatol 1997; 22: 244-245 https://doi.org/10.1111/j.1365-2230.1997.tb01079.x
  22. El-On J, Witztum A, Schnur LF. Protection of Guinea pigs against cutaneous leishmaniasis by combined infection and chemotherapy. Infec Immun 1986; 51: 704-706
  23. Nahrevanian H, Dascombe MJ. Nitric oxide and reactive nitrogen intermediates during lethal and non-lethal strains of murine malaria. Parasite Immunol 2001; 23: 491-501 https://doi.org/10.1046/j.1365-3024.2001.00406.x
  24. Nahrevanian H, Dascombe MJ. Reactive nitrogen intermediate (RNI) levels inside and outside Plasmodium infected red blood cells in murine malaria. J Trop Med Parasitol 2003; 26: 13-19
  25. Nahrevanian H, Gholizadeh SJ, Farahmand M, Aghighi Z, Assmar M, Abolhassani M. Reactive nitrogen intermediate production and tolerance variability in different mouse strains after in vivo treatment with lipopolysaccharide from Salmonella abortus equi. J Microbiol Immunol Infec 2005; 38: 164-168

Cited by

  1. Nitric oxide contributes to learning and memory deficits observed in hypothyroid rats during neonatal and juvenile growth vol.65, pp.11, 2009, https://doi.org/10.1590/s1807-59322010001100021
  2. Immunomodulation by chemotherapeutic agents against Leishmaniasis vol.11, pp.11, 2011, https://doi.org/10.1016/j.intimp.2011.08.002
  3. Is topical nitric oxide and cryotherapy more effective than cryotherapy in the treatment of old world cutaneous leishmaniasis? vol.23, pp.2, 2009, https://doi.org/10.3109/09546634.2010.495380
  4. Partial Immunotherapy of Leishmaniasis by in vivo Trial of L-Arginine in Balb/c Mice Infected with Leishmania major via Nitric Oxide Pathway vol.9, pp.3, 2015, https://doi.org/10.3923/ijbc.2015.110.122